Last reviewed · How we verify
NCT04152941: RETROLA
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
trial testing Olaparib in Relapsed Ovarian Cancers Patients in 130 participants. Completed in 11 February 2020.
11 February 2020
Quick facts
| Lead sponsor | ARCAGY/ GINECO GROUP |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 130 |
| Start date | 11 October 2018 |
| Primary completion | 11 February 2020 |
| Estimated completion | 11 February 2020 |
| Sites | 28 locations across France |
Drugs / interventions tested
- Olaparib (olaparib) — full drug profile →
Conditions studied
- Relapsed Ovarian Cancers Patients — all drugs for Relapsed Ovarian Cancers Patients →
Sponsor
ARCAGY/ GINECO GROUP — full company profile →
Who can join
18 and older, female only, with Relapsed Ovarian Cancers Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04152941
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olaparib
Trials testing the same drug.
- NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
- NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
- NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
Other ARCAGY/ GINECO GROUP trials
Trials by the same sponsor.
- NCT06715241 — A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY · Phase 2 · active not recruiting
- NCT06599463 — Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric · completed
- NCT06660147 — Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer · recruiting
- NCT05364905 — Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Ca · completed
- NCT04256213 — COL Immunotherapy Before Radiochimio + Ipilimumab · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04152941 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ARCAGY/ GINECO GROUP
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04152941.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing